Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.80
Bid: 112.80
Ask: 113.20
Change: -0.20 (-0.18%)
Spread: 0.40 (0.355%)
Open: 110.80
High: 115.00
Low: 110.80
Prev. Close: 113.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

Mon, 27th Nov 2023 19:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Saietta Group PLC - Towcester, England-based designer, engineer and manufacturer of 'eDrive' solutions for electric vehicles - Proposes placing and subscription of new shares to raise a minimum GBP5.2 million, pricing each share at 17 pence each. This is alongside a broker option to Canaccord Genuity Ltd for an additional GBP1.0 million. The fundraising is being conducted in two tranches: around GBP1.7 million raised via the firm fundraising and a minimum of GBP4.7 million via a conditional fundraising. The fundraising is expected to satisfy the company's working capital requirements through to the end of March 2024, by which time the company is expecting to have announced a number of major commercial developments.

----------

Syncona Ltd - London-based investor in healthcare companies - Notes that its portfolio company Autolus Therapeutics PLC submits biologics licence application to US Food & Drug Administration for obecabtagene autoleucel for patients with relapsed/refractory adult B-Cell acute lymphoblastic leukaemia. Says submission is based on data from the Felix study. Says Autolus has also made "significant" progress in preparing its manufacturing footprint for the planned commercial launch of obe-cel, with its new 70,000 square foot commercial manufacturing facility, The Nucleus, which has an initial designed capacity of 2,000 batches per year. Pending approval from the Food & Drug Administration for the biologics licence application submission, the company expects to initiate its commercial launch of obe-cel in the US in 2024. It also expects to file a marketing authorisation application for obe-cel with the European Medicines Agency in the first half of 2024.

----------

Molten Ventures PLC - London-based venture capital firm - Completes GBP55.0 million placing and subscription of 20.4 million new shares priced at 270p each, representing around 13% of all shares. The retail offer remains open and is expected to close on Tuesday at 1500 GMT.

----------

Quadrise PLC - London-based residual oil technology company - Says all resolutions pass at annual general meeting, but notes resolution 3 only passed with 68% of shareholders voting in favour. Resolution 3 relates to re-appointing Non-Executive Director Dilip Shah, who is to retire by rotation. The company says on this: "The board is committed to continuing our engagement with shareholders to understand the views of those who voted against resolution 3 and will consult with them over the next few months to listen carefully to feedback and determine any next steps."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
19 Dec 2019 08:58

Syncona Commits USD80 Million Investment Into Freeline Therapeutics

Syncona Commits USD80 Million Investment Into Freeline Therapeutics

Read more
19 Dec 2019 07:53

Syncona commits $80m to Freeline

(Sharecast News) - Healthcare company Syncona said it had made an $80m (£61.1m) funding commitment to biotech company Freeline.

Read more
9 Dec 2019 09:32

Syncona upbeat on latest data from Autolus Therapeutics

(Sharecast News) - Syncona shares were just above the waterline on Monday morning, after two updates from its portfolio company Autolus Therapeutics, in which it announced new data at the American Society of Hematology (ASH) annual meeting in Orlando, Florida.

Read more
9 Dec 2019 08:31

Syncona And Arix Note Positive New Data From Portfolio Firm Autolus

Syncona And Arix Note Positive New Data From Portfolio Firm Autolus

Read more
21 Nov 2019 10:47

Syncona Adds Azeria Therapeutics To Portfolio As Net Assets Take Hit

Syncona Adds Azeria Therapeutics To Portfolio As Net Assets Take Hit

Read more
21 Nov 2019 08:34

Syncona sees negative returns as it continues to invest in portfolio firms

(Sharecast News) - Healthcare investment company Syncona reported net assets of £1.37bn in its interim results on Thursday, down from £1.46bn at the end of the last financial year.

Read more
3 Sep 2019 08:18

Syncona Provides GBP83 Million In Funding For Two Portfolio Companies

(Alliance News) - Syncona Ltd said Tuesday it has made investments totalling GBP83.1 million in two companies in separate Series B financing rounds.The FTSE 250 healthcare-focused firm made

Read more
3 Sep 2019 07:58

Syncona invests ?83.1m in Gyroscope and Achilles

(Sharecast News) - Syncona on Tuesday confirmed investments of £48.0m in retinal gene therapy group Gyroscope Therapeutic and £35.1m in cancer immunotherapies developer Achilles Therapeutics.

Read more
12 Aug 2019 11:45

CORRECT: Syncona Quarterly Net Asset Value Higher On Blue Earth Sale

(Correcting that the net asset value per share as at March 31 was 216.8p, meaning NAV decreased over the course of the quarter.)(Alliance News) - Healthcare investor Syncona Ltd said its in

Read more
12 Aug 2019 09:30

Syncona Net Asset Value Lifted In First Quarter By Blue Earth Sale

(Alliance News) - Healthcare investor Syncona Ltd said Thursday its net asset value rose in the first quarter of its financial year, despite a drop in the value of its portfolio due to a declining

Read more
9 Aug 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 12 August ClarksonHalf Year ResultsSynconaQuarterly 13 Year Year

Read more
8 Jul 2019 09:04

Syncona's Freeline Therapeutics Reports Results From Haemophilia Trial

(Alliance News) - Healthcare-focused investment firm Syncona Ltd said Monday that portfolio company Freeline Therapeutics has published 12-month data from an ongoing trial in haemophilia B, and a

Read more
27 Jun 2019 09:47

Syncona Disposes Stake In Blue Earth Diagnostics To Bracco Imaging

(Alliance News) - Investment firm Syncona Ltd on Thursday said it has agreed to sell its portfolio company Blue Earth Diagnostics to Bracco Imaging for USD450 million plus closing adjustment at in

Read more
13 Jun 2019 09:32

Syncona Scraps Dividend To Focus On "Capital Intensive" Portfolio

(Alliance News) - Life sciences investor Syncona Ltd on Thursday reported a "strong" annual performance, with core life sciences firms doing well, while it is also to halt is paying a to

Read more
6 Jun 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 7 June Seneca Global Income & Growth TrustFull Year ResultsMonday 10 traffic 11

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.